FLGC
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
Flora Growth earns a Neutral rating with a 42.8 composite score and low conviction of 2/5. Regulatory is the strongest pillar at 50, supported by a 55 jurisdiction posture and an 80 enforcement subscore, while weak filing cadence limits the contribution. Fundamentals follow at 45, with strong revenue-growth scoring offset by thin profitability, constrained scale, and limited cash-runway support. Market contributes 40 because no quote was available through institutional pricing feeds, restricting confirmation from trading data. Editorial ranks last at 30, reflecting no newsroom or brief activity in CIN newsroom coverage. The combined profile supports the Neutral band rather than a more constructive stance, particularly given the stretched financial condition.
Licensed fundamentals data show year-over-year revenue growth near 35%, the clearest operating strength and the basis for an 84.7 revenue-growth subscore. That expansion has not translated into adequate earnings quality: gross margin is approximately 21%, operating margin is negative by roughly 34%, EBITDA is a loss of about $13.7 million, and net income is a loss approaching $16 million. A market capitalization near $5.8 million reinforces the zero contribution from the market-cap tier, while a cash-burn ratio above 2.3 and a cash-runway subscore of 15 keep the balance-sheet assessment stretched. Primary regulatory filings show no dated latest filing and no recorded regulatory events across either the past 90 or 180 days. The resulting cadence subscore of 25 constrains an otherwise firmer regulatory profile, despite no enforcement hits.
The forward catalyst sits within the regulatory pillar because it already provides the highest contribution and contains the most direct path to a higher composite. A renewed sequence of timely primary regulatory filings would lift the weakest component of that pillar, improve visibility into revenue conversion and operating losses, and provide a firmer basis for licensed fundamentals data and CIN newsroom coverage. The absence of enforcement hits preserves that opportunity, but stronger cadence requires documented execution rather than silence. The single most important signal to watch is the appearance of a current primary regulatory filing that restores reporting cadence.
- SEC CIK
- 0001790169
- Website
- Company website
- Market cap
- $5.8M
- Enterprise value
- $71.6M
- Price to book
- 0.33
- Price to sales
- 0.37
- EV / EBITDA
- -1.00
- Revenue (TTM)
- $57.6M
- Gross profit (TTM)
- $12.1M
- EBITDA
- $-13.7M
- Operating margin
- -33.5%
- Profit margin
- -27.7%
- Rev growth YoY
- 34.7%
- Return on equity
- -45.3%
- Return on assets
- -17.5%
- EPS (TTM)
- $-41.09
- EPS est. current year
- $-23.01
- Wall St. target price
- $30.00
- Shares outstanding
- 0.7M
- Insider ownership
- 16.6%
- Institutional ownership
- 2.1%
- Beta
- 1.87
- Full-time employees
- 64
- GICS sector
- Financial Services
- GICS industry
- Asset Management
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for FLGC (FLGC)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for FLGC (FLGC), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for FLGC are maintained by Cannabis Investor News and refreshed throughout the trading day.